Format

Send to:

Choose Destination
See comment in PubMed Commons below
Vaccine. 2011 Dec 9;30(1):9-13. doi: 10.1016/j.vaccine.2011.10.054. Epub 2011 Oct 30.

Control of methicillin resistant Staphylococcus aureus infection utilizing a novel immunostimulatory peptide.

Author information

  • 1Department of Biology, Center for Microbial Sciences, San Diego State University, 5500 Campanile Drive, San Diego, CA 92182, USA.

Abstract

The emergence of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) is a serious health concern worldwide that requires new therapeutic approaches that extend beyond the development and use of new antibiotics. In this study, a conformationally biased, response-selective agonist of human C5a, known as EP67, was used to induce host innate immunity as a therapeutic method of reducing CA-MRSA infections. Using a murine model of dermonecrosis we show that EP67 treatment effectively limits CA-MRSA infection by promoting cytokine synthesis and neutrophil influx. In contrast, EP67 was ineffective in reducing lesion formation in C5a receptor (CD88(-/-)) knockout mice, indicating that EP67 activates host innate immunity by engagement of CD88 bearing cells. These results suggest that EP67 may serve as a novel immunotherapeutic for prevention and treatment of CA-MRSA dermal infection.

Copyright © 2011 Elsevier Ltd. All rights reserved.

PMID:
22044742
[PubMed - indexed for MEDLINE]
PMCID:
PMC3229650
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk